Výsledky vyhledávání - "Hélène Ste-Croix"

Data from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

Nonselective inhibitors of human histone deacetylases (HDAC) are known to have antitumor activity in mice in vivo, and several of them are under clinical investigation. The first of these, Vorinostat (SAHA), has been approved for treatment of cutaneo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37be0158a4c3ff3f1783a4ed1271cd1d
https://doi.org/10.1158/1535-7163.c.6531123.v1

Zobrazit plný text záznamu

Supplementary Table 1 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

Supplementary Table 1 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::489f53ab3050b1c461753e8c3470afee
https://doi.org/10.1158/1535-7163.22483368

Zobrazit plný text záznamu

Supplementary Table 2 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

Supplementary Table 2 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dfa14777fa57c3391ea3a30617e6ac2
https://doi.org/10.1158/1535-7163.22483365.v1

Zobrazit plný text záznamu

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

Publikováno v: Molecular Cancer Therapeutics. 7:759-768

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d3917799eb55abeb62670a39bd84c56
https://doi.org/10.1158/1535-7163.mct-07-2026

Zobrazit plný text záznamu

N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors

Publikováno v: Bioorganicmedicinal chemistry letters. 19(23)

A series of N-(4-(6,7-disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides targeting c-Met and VEGFR2 tyrosine kinases was designed and synthesized. The compounds were potent against these two enzymes with IC(50)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a9020f89c6b464506c2acebb912014e
https://pubmed.ncbi.nlm.nih.gov/19854051

Zobrazit plný text záznamu

Abstract 1790: The combination of MGCD265, a Met/VEGFR inhibitor in clinical development, and erlotinib potently inhibits tumor growth by altering multiple pathways including glycolysis

Autor: Hélène Ste-Croix, Jeffrey M. Besterman, Marielle Fournel, Normand Beaulieu, Claire Bonfils, Christiane R. Maroun

Publikováno v: Cancer Research. 72:1790-1790

MGCD265 is an oral, multitargeted, receptor tyrosine kinase inhibitor in clinical development. MGCD265 targets the Met, VEGFR1, 2, 3, Tie2 and Ron receptor tyrosine kinases and blocks key pathways regulating cancer development and progression. Met-ta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6cbcd1d94d8857f4f40a99cb49b83428
https://doi.org/10.1158/1538-7445.am2012-1790

Zobrazit plný text záznamu

Abstract 3610: Potent preclinical anti-tumor activity of MGCD265, an oral Met/VEGFR multitargeted kinase inhibitor in clinical development, in combination with taxanes

Autor: Marielle Fournel, Isabelle Dupont, Normand Beaulieu, Christian Lemoyne, Hélène Ste-Croix, Christiane R. Maroun, Claire Bonfils, Jeffrey M. Besterman, James Wand

Publikováno v: Cancer Research. 71:3610-3610

MGCD265, a multitargeted receptor tyrosine kinase inhibitor in clinical development, inhibits the activation of Met, VEGFR1, 2, 3, Tie-2 and Ron. Met is a promising molecular target for the development of cancer therapeutics and is found overexpresse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::935fbac1ce57bb752271c0827e9146dd
https://doi.org/10.1158/1538-7445.am2011-3610

Zobrazit plný text záznamu

Abstract 3612: Potent preclinical anti-tumor activity of MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in Phase II clinical development, in combination with an EGFR inhibitor

Autor: Marielle Fournel, Marja Dubay, Christian Lemoyne, Stephen William Claridge, Arkadii Vaisburg, Michael Mannion, Robert E. Martell, Lubo Isakovic, Oscar Mario Saavedra, Franck Raeppel, Claire Bonfils, Normand Beaulieu, Hélène Ste-Croix, Carole Beaulieu, Stephane Raeppel, Jeffrey M. Besterman, James Wang, Isabelle Dupont, Christiane R. Maroun

Publikováno v: Cancer Research. 70:3612-3612

MGCD265 is an oral multitargeted receptor tyrosine kinase inhibitor in Phase II clinical development. MGCD265 targets the Met receptor tyrosine kinase and blocks Met activities which contribute to cancer development and progression such as cell proli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9a498a92e14cb23991980fa949b80090
https://doi.org/10.1158/1538-7445.am10-3612

Zobrazit plný text záznamu

Abstract 3609: MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in Phase II clinical development, potently inhibits clinically relevant Met mutants

Autor: Isabelle Dupont, Claire Bonfils, Christiane R. Maroun, Arkadii Vaisburg, Lubo Isakovic, Stephen William Claridge, Jeffrey M. Besterman, Marja Dubay, Stephane Raeppel, Hélène Ste-Croix, Normand Beaulieu, Franck Raeppel, Oscar Mario Saavedra, Michael Mannion

Publikováno v: Cancer Research. 70:3609-3609

MGCD265 is a multitargeted receptor tyrosine kinase inhibitor in Phase II clinical development, which inhibits the activation of regulators of cancer development and progression by targeting Met, the three members of the VEGFR family, Tie-2 and Ron.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b557e324e246583523bbe6c4a1eb6659
https://doi.org/10.1158/1538-7445.am10-3609

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání